Two Phase 3 Uveitis Trials Support Brepocitinib Steroid Sparing
Brepocitinib met the primary and multiplicity-controlled secondary endpoints in both CLARITY phase 3 studies of noninfectious uveitis. The independent replication and clinically relevant steroid taper make this a strong late-stage immunology signal; full safety…
